150 related articles for article (PubMed ID: 33243034)
41. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
42. Case report: Systemic presentation of ALK-positive Histiocytosis.
Wei Y; Zhang R; Lin D; Chen X; Li L; Huang H
Front Oncol; 2024; 14():1366766. PubMed ID: 38706599
[TBL] [Abstract][Full Text] [Related]
43. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
44. A rare double ALK fusion variant EML4-ALK and CDK15-ALK in lung adenocarcinoma and response to crizotinib: A case report.
Guo J; Shi J; Yao M; Jin Y; Liu D; Liu W; Wang K; Jiang D
Medicine (Baltimore); 2020 Nov; 99(45):e22631. PubMed ID: 33157918
[TBL] [Abstract][Full Text] [Related]
45. A Clinicopathological Study of 29 Spitzoid Melanocytic Lesions With ALK Fusions, Including Novel Fusion Variants, Accompanied by Fluorescence In Situ Hybridization Analysis for Chromosomal Copy Number Changes, and Both TERT Promoter and Next-Generation Sequencing Mutation Analysis.
Kastnerova L; Martinek P; Grossmann P; Steiner P; Vanecek T; Kyclova J; Ferak I; Zalud R; Slehobr O; Svajdler P; Sulc M; Bradamante M; Banik M; Hadravsky L; Sticova E; Hajkova V; Ptakova N; Michal M; Kazakov DV
Am J Dermatopathol; 2020 Aug; 42(8):578-592. PubMed ID: 32701692
[TBL] [Abstract][Full Text] [Related]
46. Durable response to the ALK inhibitor alectinib in inflammatory myofibroblastic tumor of the head and neck with a novel SQSTM1-ALK fusion: a case report.
Honda K; Kadowaki S; Kato K; Hanai N; Hasegawa Y; Yatabe Y; Muro K
Invest New Drugs; 2019 Aug; 37(4):791-795. PubMed ID: 30790150
[TBL] [Abstract][Full Text] [Related]
47. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
[TBL] [Abstract][Full Text] [Related]
48. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
49. Molecular investigation of ALK-rearranged epithelioid fibrous histiocytomas identifies CLTC as a novel fusion partner and evidence of fusion-independent transcription activation.
Georgantzoglou N; Green D; Winnick KN; Sumegi J; Charville GW; Bridge JA; Linos K
Genes Chromosomes Cancer; 2022 Aug; 61(8):471-480. PubMed ID: 35289445
[TBL] [Abstract][Full Text] [Related]
50. Targeted next-generation sequencing revealed distinct clinicopathologic and molecular features of VCL-ALK RCC: A unique case from an older patient without clinical evidence of sickle cell trait.
Wang XT; Fang R; Ye SB; Zhang RS; Li R; Wang X; Ji RH; Lu ZF; Ma HH; Zhou XJ; Xia QY; Rao Q
Pathol Res Pract; 2019 Nov; 215(11):152651. PubMed ID: 31563285
[TBL] [Abstract][Full Text] [Related]
51. [Anaplastic lymphoma kinase-translocation renal cell carcinoma: clinical and pathological analysis].
Di SH; Wang XT; Xia QY; Lu ZF; Ma HH; Zhang RS; Wang X; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2022 Jan; 51(1):28-32. PubMed ID: 34979750
[No Abstract] [Full Text] [Related]
52. Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ; Zhu VW; Yoda S; Yeap BY; Schrock AB; Dagogo-Jack I; Jessop NA; Jiang GY; Le LP; Gowen K; Stephens PJ; Ross JS; Ali SM; Miller VA; Johnson ML; Lovly CM; Hata AN; Gainor JF; Iafrate AJ; Shaw AT; Ou SI
J Clin Oncol; 2018 Apr; 36(12):1199-1206. PubMed ID: 29373100
[TBL] [Abstract][Full Text] [Related]
53. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
[TBL] [Abstract][Full Text] [Related]
54. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
[TBL] [Abstract][Full Text] [Related]
55. Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report.
Son SM; Woo CG; Lee OJ; Kim YJ; Lee HC
Oncol Lett; 2023 Jun; 25(6):227. PubMed ID: 37153035
[TBL] [Abstract][Full Text] [Related]
56. A novel
Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
[TBL] [Abstract][Full Text] [Related]
57. SPP1 overexpression is associated with poor outcomes in ALK fusion lung cancer patients without receiving targeted therapy.
Ji X; Liu Y; Mei F; Li X; Zhang M; Yao B; Wu R; You J; Pei F
Sci Rep; 2021 Jul; 11(1):14031. PubMed ID: 34234236
[TBL] [Abstract][Full Text] [Related]
58. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
[TBL] [Abstract][Full Text] [Related]
59. Epithelioid fibrous histiocytoma: molecular characterization of ALK fusion partners in 23 cases.
Dickson BC; Swanson D; Charames GS; Fletcher CD; Hornick JL
Mod Pathol; 2018 May; 31(5):753-762. PubMed ID: 29327718
[TBL] [Abstract][Full Text] [Related]
60. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases.
Gascoyne RD; Lamant L; Martin-Subero JI; Lestou VS; Harris NL; Müller-Hermelink HK; Seymour JF; Campbell LJ; Horsman DE; Auvigne I; Espinos E; Siebert R; Delsol G
Blood; 2003 Oct; 102(7):2568-73. PubMed ID: 12763927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
